AA-Ipravent · DIN 02126222 · 250 mcg/mL · Inh Sol-20mL Pk
Limited Use, Reason for Use code 256, 257, 258, 259 requiredMarketed · checked November 19, 2026
StatusLimited Use, Reason for Use code 256, 257, 258, 259 required
Write on scriptone applicable Reason for Use code, 256 or 257 or 258 or 259 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 256, 257, 258, 259
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 256
Patients who have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 257
Patients with cystic fibrosis in whom nebulizer therapy is indicated;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 258
Patients with severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 259
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
AA-Ipravent · DIN 02126222
Manufacturer: A A Pharma Inc.; listing date 2000-11-30
Health Canada: Marketed since 2024-03-28 · brand AA-IPRAVENT · ATC R03BB01 IPRATROPIUM BROMIDE · form Solution · route Inhalation · ingredients IPRATROPIUM BROMIDE 250 MCG/ML · company Aa pharma inc · schedule Prescription
AA-Ipravent: Formulary list price $6.31 per unit (the source does not state the unit; exact figure $6.3140). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02126222)
Source record
DIN 02126222: AA-Ipravent
Raw flags: sec12=Y, sec3=Y
Item: 120800039; group id 205; item number 0374; lccId 00030; manufacturer id AAP
Source form: Inh Sol-20mL Pk; strength: 250mcg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $6.3140; ministry $6.3140
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02126222
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16947
Interchangeable products
Atrovent · DIN 00731439 · not recorded
Novo-Ipramide · DIN 02210479 · $6.3140
PMS-Ipratropium · DIN 02231136 · $6.3140
Shortage status: not checked (no credentials)